Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
-
Published:2021-10-29
Issue:1
Volume:12
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Wei Jia, Matthews Philippa C., Stoesser NicoleORCID, Maddox Thomas, Lorenzi Luke, Studley Ruth, Bell John I., Newton John N., Farrar Jeremy, Diamond Ian, Rourke Emma, Howarth Alison, Marsden Brian D., Hoosdally Sarah, Jones E. Yvonne, Stuart David I., Crook Derrick W., Peto Tim E. A., Pouwels Koen B.ORCID, Walker A. Sarah, Eyre David W.ORCID, Thomas Tina, Cook Duncan, Ayoubkhani Daniel, Black Russell, Felton Antonio, Crees Megan, Jones Joel, Lloyd Lina, Sutherland Esther, Pritchard Emma, Vihta Karina-Doris, Doherty George, Kavanagh James, Chau Kevin K., Hatch Stephanie B., Ebner Daniel, Ferreira Lucas Martins, Christott Thomas, Dejnirattisai Wanwisa, Mongkolsapaya Juthathip, Cameron Sarah, Tamblin-Hopper Phoebe, Wolna Magda, Brown Rachael, Cornall Richard, Screaton Gavin, Lythgoe Katrina, Bonsall David, Golubchik Tanya, Fryer Helen, Cox Stuart, Paddon Kevin, James Tim, House Thomas, Robotham Julie, Birrell Paul, Jordan Helena, Sheppard Tim, Athey Graham, Moody Dan, Curry Leigh, Brereton Pamela, Jarvis Ian, Godsmark Anna, Morris George, Mallick Bobby, Eeles Phil, Hay Jodie, VanSteenhouse Harper, Lee Jessica, White Sean, Evans Tim, Bloemberg Lisa, Allison Katie, Pandya Anouska, Davis Sophie, Conway David I., MacLeod Margaret, Cunningham Chris,
Abstract
AbstractUnderstanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited. Here we estimated antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. A latent class model classified 24% of participants as ‘non-responders’ not developing anti-spike antibodies, who were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms. Among those who seroconverted, using Bayesian linear mixed models, the estimated anti-spike IgG peak level was 7.3-fold higher than the level previously associated with 50% protection against reinfection, with higher peak levels in older participants and those of non-white ethnicity. The estimated anti-spike IgG half-life was 184 days, being longer in females and those of white ethnicity. We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.
Funder
Department of Health and Social Care
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference54 articles.
1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/. 2. Overbaugh, J. Understanding protection from SARS-CoV-2 by studying reinfection. Nat. Med. 26, 1680–1681 (2020). 3. Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet397, 1459–1469 (2021). 4. Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med.384, 533–540 (2021). 5. Bubar, K. M. et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 371, 916–921 (2021).
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|